<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276614</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453541</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-0412011-01</secondary_id>
    <secondary_id>MILLENNIUM-X05145</secondary_id>
    <nct_id>NCT00276614</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with
      metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine, preliminarily, the efficacy of bortezomib in patients with metastatic
           non-clear cell renal cell carcinoma in terms of objective response rate after a minimum
           of 2 courses of treatment.

      Secondary

        -  Correlate clinical response in these patients with baseline von Hippel-Lindau expression
           and nuclear factor-KB activity.

      OUTLINE: This is an open-label study.

      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats
      every 21 days for up to 6 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed at 1 month and then periodically
      for 2 years.

      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Velcade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <arm_group_label>Velcade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed pure non-clear cell renal cell carcinoma (RCC)

          -  Distant metastatic disease (Tx, Nx, M1)

          -  Tumor expresses wild-type von Hippel-Lindau tumor suppressor gene/protein

          -  Measurable disease on imaging scan (≥ 1 cm)

          -  Brain metastases allowed provided they have been treated with surgery and/or radiation
             therapy and show no evidence of progression on cerebral CT or MRI scan 2 months
             following surgery and/or radiation therapy.

          -  Life expectancy ≥ 3 months

          -  Karnofsky performance status ≥ 60%

          -  Negative pregnancy test

          -  Fertile patients must use an acceptable method of contraception

          -  No other major illnesses likely to limit survival

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1, 000/mm^3

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

          -  Creatinine clearance ≥ 30 mL/min OR creatinine ≤ 2 mg/dL

          -  ALT or AST ≤ 2.5 times upper limit of normal

          -  At least 4 weeks since prior radiotherapy and recovered

          -  More than 30 days since any other prior investigational drugs

        Exclusion Criteria:

          -  active CNS metastases

          -  pregnant or nursing

          -  myocardial infarction within the past 6 months

          -  New York Heart Association class III or IV heart failure

          -  uncontrolled angina

          -  severe uncontrolled ventricular arrhythmias

          -  electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  Peripheral neuropathy ≤ grade 1

          -  hypersensitivity to bortezomib, boron, or mannitol

          -  history of a non-RCC malignancy within the past 5 years except basal cell carcinoma of
             the skin

          -  serious medical or psychiatric illness that would preclude study participation

          -  prior cytotoxic chemotherapy for this cancer

          -  other concurrent investigational therapy

          -  concurrent chemotherapy, immunotherapy, or hormonal therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B. Rettig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <results_first_submitted>March 27, 2012</results_first_submitted>
  <results_first_submitted_qc>March 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2012</results_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>papillary renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from April 2006 through May 2009 at outpatient oncology clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib</title>
          <description>Bortezomib 1.3 mg/m2 given on days 1, 4, 8, 11 of a 21 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progression of disease under study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib</title>
          <description>Bortezomib 1.3 mg/m2 given on days 1, 4, 8, 11 of a 21 day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="26" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses</title>
        <time_frame>2 months</time_frame>
        <population>2 subjects were excluded from analysis as they completed less than 2 cycles of study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib</title>
            <description>Bortezomib 1.3 mg/m2 given on days 1, 4, 8, 11 of a 21 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses</title>
          <population>2 subjects were excluded from analysis as they completed less than 2 cycles of study therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning of treatment through 30 days post last treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib</title>
          <description>Bortezomib 1.3 mg/m2 given on days 1, 4, 8, 11 of a 21 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Approval of several agents for management of renal cell carcinoma rendered accrual to this trial quite difficult.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Matthew Rettig, M.D.</name_or_title>
      <organization>David Geffen School of Medicine at UCLA</organization>
      <phone>310-794-3565</phone>
      <email>mrettig@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

